Wayne K. Goodman, MD, Receives Career Achievement Award from International OCD Foundation
Wayne K. Goodman, MD, Chairman and the Esther and Joseph Klingenstein Professor in the Department of Psychiatry at Mount Sinai, will receive the 2012 Outstanding Career Achievement Award from the International OCD (Obsessive Compulsive Disorder) Foundation. Dr. Goodman will receive the honor at the 19th Annual International OCD Foundation Conference in Chicago, during the keynote address on July 28, 2012.
For 25 years, Dr. Goodman has made groundbreaking contributions to the field of psychiatry that have changed the way clinicians evaluate, diagnose, and treat patients suffering from OCD and related disorders. His clinical experience and research findings have led to new treatments that have improved the quality of life for patients and their families.
Most notably, Dr. Goodman is the principal developer of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), which has been the gold standard for evaluating OCD for nearly 20 years. Y-BOCS is also used extensively throughout research and clinical practice to evaluate the severity of OCD symptoms and measure response to treatment.
An internationally recognized authority on OCD, Dr. Goodman has pioneered research relating to the neurobiology, phenomenology, and treatment of OCD and related disorders. He has published more than 250 articles and serves on the editorial board of several major medical journals.
Dr. Goodman was one of the first investigators to test and establish the efficacy of Selective Serotonin Reuptake Inhibitors (SSRIs) in OCD. In addition, he developed the use of adjunctive antipsychotic medications in SSRI-resistant OCD.
He is an expert in the development and application of deep brain stimulation (DBS). This neurosurgical procedure involves implanting a device, which delivers electrical stimulation directly to the brain, to treat treatment-resistant OCD. Dr. Goodman works closely in the operating room with neurosurgeons to test the emotional and behavioral effects of the device when the patient is awake. After surgery, he monitors the patient and adjusts the settings of the device as needed.
Dr. Goodman works closely with Mount Sinai’s Friedman Brain Institute to conduct research on neuropsychiatric disorders such as mood depression, autism, schizophrenia, Alzheimer's disease, and bipolar disorder. Dr. Goodman is an expert psycho-pharmacologist and previously served as Chair of the Food and Drug Administration's Psychopharmacologic Drug Advisory Committee.
In 1986, while at Yale University, Dr. Goodman co-founded the International OCD Foundation, which is still the primary national patient advocacy organization for OCD and related disorders. The international not-for-profit organization is made up of people with OCD and related disorders, as well as their families, friends, professionals, and others. For ten years, Dr. Goodman served as the first Chair of the International OCD Foundation’s Scientific Advisory Board.
Prior to joining Mount Sinai, Dr. Goodman served as Director of the Division of Adult Translational Research and Treatment Development at the National Institutes of Mental Health (NIMH) in Bethesda, Maryland. Before the NIMH, Dr. Goodman served as Chair of the Department of Psychiatry at the University of Florida College of Medicine for nine years. Dr. Goodman was an undergraduate at Columbia University, received his medical degree from Boston University School of Medicine, and completed his residency and fellowship in psychiatry at Yale University, where he remained a faculty member until 1993.
At the Mount Sinai OCD Treatment Center, Dr. Goodman leads a team of multidisciplinary clinicians who use evidence-based science to treat Tic, OCD, and related disorders across the lifespan. The Division of Tics, Obsessive-compulsive, and Related Disorders (DTOR) specialize in treating patients of all ages who suffer from these conditions. A range of different treatment modalities is available, including Cognitive Behavioral Therapy and medications. Investigational medication trials and DBS are available for treatment-resistant cases.
Patients have access to expert consultations, comprehensive evaluations, and ongoing treatment programs. Ultimately, the goal of the DTOR is to discover the causes of Tic, Obsessive-compulsive and Related Disorders, so that new and better treatments can be developed.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.